Juvelook

Juvelook is a family of hybrid injectable products combining poly-D,L-lactic acid (PDLLA) particles with hyaluronic acid (HA). The current Korean family includes five named presentations with three total-content tiers. Product name, PDLLA quantity, HA quantity, particle characteristics, preparation, and intended use must remain visible.

Juvelook should not be treated as one concentration, and Juvelook Volume should not be treated as a casual synonym for every 200 mg presentation.

Quick reference

Field	Juvelook family
Material system	PDLLA particles + HA
Current Korean family	Juvelook i, Juvelook Skin, Juvelook, Juvelook Volume, Juvelook G
Listed total content	30 mg, 50 mg, or 200 mg depending on presentation
Korean classification	VAIM presents the family as Class IV medical devices in the `soft-tissue repair material` category
Product form	Product-specific dry presentation requiring preparation
Immediate-effect interpretation	Must account for HA, prepared fluid, and PDLLA as different contributors
Company	VAIM
Main comparison	AestheFill is PDLLA + CMC rather than the same PDLLA + HA system

VAIM’s current Korean product page lists the compositions and intended-use wording for all five presentations (Juvelook product information 🔗).

Current Korean product family

Presentation	PDLLA	HA	Total listed content	Company-reported particle context
Juvelook i	25.5 mg	4.5 mg	30 mg	Company interview describes a nominal 20 μm particle size
Juvelook Skin	25.5 mg	4.5 mg	30 mg	Not identified on the reviewed product page
Juvelook	42.5 mg	7.5 mg	50 mg	Company interview describes a nominal 25 μm particle size
Juvelook Volume	170 mg	30 mg	200 mg	Company interview describes a nominal 40 μm particle size
Juvelook G	170 mg	30 mg	200 mg	Company interview describes a nominal 65 μm particle size

The composition values come from VAIM’s official product page. The nominal particle-size statements come from a 2025 interview published on the company’s media page and should be treated as company-reported product characterization, not as an independent comparative clinical result (VAIM interview 🔗).

The same PDLLA and HA quantities do not prove that Juvelook i and Juvelook Skin—or Juvelook Volume and Juvelook G—are interchangeable. Product naming and particle characterization indicate that formulation identity extends beyond total content.

How the five Korean presentations are positioned

VAIM’s public material separates the five Korean presentations by more than total content. Some distinctions are supported only by company interviews or launch material rather than a reviewed IFU or independent comparative study.

Presentation	Publicly described distinction	Evidence boundary
Juvelook i	30 mg total; a 2025 company interview describes a nominal 20 μm particle size and positions it for thinner areas and fine wrinkles	Company-reported particle characterization and commercial positioning
Juvelook Skin	30 mg total; launched in June 2026 with a company-described one-patient, one-vial use environment	The reviewed public product page does not identify a particle specification that distinguishes it from Juvelook i
Juvelook	50 mg total; the same interview describes a nominal 25 μm particle size	Published study protocols involving this presentation do not define the other four products
Juvelook Volume	200 mg total; the interview describes a nominal 40 μm particle size	`Volume` should not be used as a generic name for every 200 mg presentation
Juvelook G	200 mg total; the interview describes a nominal 65 μm particle size and positions it for broader areas or deeper wrinkles	Company positioning is not an independently established indication or comparative outcome

The positioning statements come from VAIM-hosted media rather than the common intended-use wording on the current Korean product page (Juvelook i and G company interview 🔗; Juvelook Skin launch 🔗).

Same listed content does not mean the same product

Juvelook i and Juvelook Skin both list 25.5 mg PDLLA plus 4.5 mg HA. Juvelook Volume and Juvelook G both list 170 mg PDLLA plus 30 mg HA. Those shared quantities do not establish identical particle distributions, package presentations, preparation instructions, placement guidance, or clinical roles.

Where a specification is not present in the reviewed product information, it should remain not identified rather than being reconstructed from the product name, package image, launch positioning, or another family member.

Korean device classification and intended use

VAIM’s current Korean product page presents the Juvelook family as Class IV medical devices in the product category translated here as soft-tissue repair material (조직수복용재료). It gives the same intended-use wording for all five presentations: subcutaneous injection of polylactide and HA for temporary improvement of adult facial wrinkles through physical restoration (Juvelook product information 🔗).

This is company-hosted Korean product information. The exact MFDS product record, approval number, legal manufacturer, approval holder, approved IFU, and presentation-specific instructions should still be verified from the controlling record before those details are stated as regulator-confirmed.

The shared public intended-use wording does not prove that the five products have identical instructions. It also does not convert company media discussion of fine wrinkles, pores, scars, thinner areas, broader areas, or deeper wrinkles into separate approved indications.

Patented design and evidence boundaries

VAIM’s technology page states that it holds patent rights relating to the manufacture of Juvelook’s porous, reticulated PDLLA structure and to a PDLLA + HA composition complex (Juvelook technology 🔗). These statements support how the company describes the product design; they do not by themselves establish a clinical advantage.

Keep four questions separate:

Question	What the reviewed company source supports
Is a patented technology claimed?	Yes, for the described particle-manufacturing method and PDLLA + HA composition technology
Does the company describe a porous, reticulated structure?	Yes
Does that establish a specific clinical outcome?	No; clinical outcomes require product- and protocol-specific evidence
Does it prove superiority over another PDLLA product?	No; comparative safety, degradation, injectability, distribution, or nodule claims require compatible comparative evidence

Approved wording and broader clinical discussion

VAIM’s Korean product page describes the intended use as subcutaneous injection of polylactide and HA for temporary improvement of adult facial wrinkles through physical restoration.

That approved wording should remain separate from company media, published studies, and common clinical discussion involving:

fine lines
pores or texture
acne scars
tear troughs
nasolabial folds
broader volumization
body use

A study or company presentation involving one of these objectives does not make it a universal approved indication for every Juvelook product.

Preparation is presentation-specific

Published Juvelook studies use heterogeneous preparation methods. For example, a preliminary whole-face study used the 50 mg Juvelook presentation and a 10 mL mixture containing additional HA, lidocaine, and saline (Journal of Cosmetic Dermatology 🔗). A 2026 nasolabial-fold case series instead reported a 6 mL saline preparation (Juvelook nasolabial-fold case series 🔗).

These are study protocols, not evidence that either method:

is the controlling Korean IFU
applies to all five presentations
can be transferred between anatomical areas
produces equivalent particle distribution or clinical behavior

Document the exact product, reconstitution liquid, total volume, additives, preparation method, standing time, device, anatomy, and source type whenever technique is discussed.

Immediate and delayed components

Juvelook is a hybrid product. Its clinical sequence should not be summarized as if HA and PDLLA perform the same role.

Phase	Interpretation
Immediately after injection	Prepared fluid, HA, edema, and physical distribution can all affect appearance
Early follow-up	Fluid-related and inflammatory changes evolve
Later follow-up	Published discussion focuses on tissue response associated with the PDLLA component

The presence of HA does not make the whole implant equivalent to an HA-only gel or establish complete reversibility with hyaluronidase.

Clinical evidence: product and protocol must stay visible

The available literature includes small prospective or preliminary studies of the 50 mg Juvelook presentation in different treatment contexts. One preliminary facial-rejuvenation study used PDLLA 42.5 mg plus HA 7.5 mg, while a 2026 nasolabial-fold case series included 20 patients with three-month follow-up after the final session.

These studies can inform product-specific questions, but limitations include:

small cohorts
short follow-up in some studies
absence of a comparator in case series
heterogeneous preparation and delivery
anatomy-specific results

Do not extrapolate “no nodules observed” in a small, short study into a class-wide or product-family guarantee.

Company and product roles

Role	Supported relationship
Brand and product family	Juvelook
Company	VAIM
Korean product information source	VAIM official Juvelook site
Legal manufacturer and approval holder	Verify from the exact product registration and IFU
Regional brand name or distributor	Market-specific

Regional names such as Lenisna or other distributor-facing identities require separate verification. Shared company or PDLLA technology does not prove identical presentation, label, or commercial role.

The VAIM company page distinguishes the Korean brand family from international manufacturer, registration, and distributor records.

Safety and limitations

Juvelook products are particulate hybrid implants. Safety interpretation should preserve:

exact presentation
particle characteristics
preparation homogeneity
placement and anatomy
HA-related and PDLLA-related components
vascular-event risk
early versus delayed nodules
inflammatory signs and infection

The smaller nominal particle size of one presentation should not be rewritten as proof of safety in thin or high-risk anatomy.

Nearby reference pages

Skin quality separates elasticity, hydration, roughness, and subjective ratings.
Immediate vs delayed effects keeps prepared fluid, HA, edema, and PDLLA visible.
South Korea regulation preserves the Korean intended-use wording and product-family boundary.
Clinical practice framework connects exact presentation to screening, consent, and follow-up.
Nodules and delayed reactions explains why HA and PDLLA components remain visible in assessment.
AestheFill vs Juvelook keeps PDLLA, HA, and exact presentation visible.
Juvelook vs Juvelook Volume separates the 50 mg and 200 mg Korean presentations and their product-specific evidence.
Ready-to-use vs reconstituted explains why preparation cannot be inferred from the material acronym.
PDLLA explains the material family and why hybrid composition matters.
AestheFill provides the closest initial PDLLA formulation comparison.
Radiesse separates a mineral-microsphere and CMC-carrier implant from PDLLA + HA.
Collagen Stimulators maps the wider product graph.